Corticosteroids for chronic obstructive pulmonary disease (COPD)ReferencesCitationsSingh JM, et al. (2002). Corticosteroid therapy for
patients with acute exacerbations of chronic obstructive pulmonary disease.
Archives of Internal Medicine, 162:
2527–2536. Alsaeedi A, et al. (2002). The effects of inhaled
corticosteroids in chronic obstructive pulmonary disease: A systematic review
of randomized placebo-controlled trials. American Journal of
Medicine, 113: 59–65. Kerstjens H, et al. (2005). Chronic
obstructive pulmonary disease. Clinical Evidence (13):
1923-1947. Highland KB, et al. (2003). Long-term effects of
inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary
disease. Annals of Internal Medicine, 138:
969–973. Calverley P, et al. (2003). Combined salmeterol and
fluticasone in the treatment of chronic obstructive pulmonary disease: A
randomised controlled trial. Lancet, 361:
449–456. Hanania NA, et al. (2003). The efficacy and safety of
fluticasone propionate (250 micrograms)/salmeterol (50 micrograms) combined in
the Diskus Inhaler for the treatment of COPD. Chest,
124: 834–843. Global Initiative for Chronic Obstructive
Lung Disease (GOLD) (2005). Executive summary (updated 2005). In
Global Strategy for the Diagnosis, Management, and Prevention
of Chronic Obstructive Pulmonary Disease. Available online:
http://www.goldcopd.com/GuidelinesResources.asp?I1=2&I2=0.
| |